{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:40:37Z","timestamp":1769604037079,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Community Oncology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.cmonc.2012.09.015","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T22:38:47Z","timestamp":1353019127000},"page":"S53-S60","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S","title":["Considerations in the initial management of follicular lymphoma"],"prefix":"10.1016","volume":"9","author":[{"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajni","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auldyn","family":"Hirschey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cmonc.2012.09.015_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cmonc.2012.09.015_bib2","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"4","key":"10.1016\/j.cmonc.2012.09.015_bib3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdg168","article-title":"Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review","volume":"14","author":"Damaj","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cmonc.2012.09.015_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3960\/jslrt.47.73","article-title":"Primary hepatic follicular lymphoma: a case report and discussion of chemotherapy and favorable outcomes","volume":"47","author":"Gomyo","year":"2007","journal-title":"J Clin Exp Hematop"},{"issue":"2","key":"10.1016\/j.cmonc.2012.09.015_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12185-010-0674-x","article-title":"Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?","volume":"92","author":"Solal-C\u00e9ligny","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmonc.2012.09.015_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/asheducation-2007.1.216","article-title":"Clinical features, prognosis and treatment of follicular lymphoma","author":"Salles","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9383","key":"10.1016\/j.cmonc.2012.09.015_bib7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"5 suppl 5","key":"10.1016\/j.cmonc.2012.09.015_bib8","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.cmonc.2012.09.015_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3816\/CLML.2010.n.086","article-title":"A decade of progress in lymphoma: advances and continuing challenges","volume":"10","author":"Flowers","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.cmonc.2012.09.015_bib10","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/10428190903093815","article-title":"Predicting transformation in follicular lymphoma","volume":"50","author":"De Jong","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.cmonc.2012.09.015_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beha.2004.06.002","article-title":"The clinical course of follicular lymphoma","volume":"18","author":"Rohatiner","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"suppl 5","key":"10.1016\/j.cmonc.2012.09.015_bib12","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdq184","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dreyling","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cmonc.2012.09.015_bib14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"80","author":"Ansell","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.cmonc.2012.09.015_bib15","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cmonc.2012.09.015_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/17.5.1013","article-title":"Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens","volume":"17","author":"Fuscoe","year":"1996","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.cmonc.2012.09.015_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/dc.21447","article-title":"Fine-needle aspiration cytology diagnosis of non-Hodgkins lymphoma in a resource-challenged environment","volume":"39","author":"Alam","year":"2010","journal-title":"Diagn Cytopathol"},{"issue":"5","key":"10.1016\/j.cmonc.2012.09.015_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cmonc.2012.09.015_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cmonc.2012.09.015_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3322\/canjclin.55.6.368","article-title":"Staging non-Hodgkin lymphoma","volume":"55","author":"Armitage","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.cmonc.2012.09.015_bib21","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cmonc.2012.09.015_bib22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cmonc.2012.09.015_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): A prospective US patient cohort treated predominantly in community practices [published online ahead of print October 5","author":"Nooka","year":"2012","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.cmonc.2012.09.015_bib24","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cmonc.2012.09.015_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cmonc.2012.09.015_bib26","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cmonc.2012.09.015_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma?","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.cmonc.2012.09.015_bib28","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cmonc.2012.09.015_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLML.2010.n.056","article-title":"Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?","volume":"10","author":"Shenoy","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.cmonc.2012.09.015_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","article-title":"Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cmonc.2012.09.015_bib31","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.cmonc.2012.09.015_bib32","first-page":"6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a)","volume":"116","author":"Ardeshna","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.cmonc.2012.09.015_bib33","first-page":"LBA-6","article-title":"Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma","volume":"118","author":"Kahl","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"10.1016\/j.cmonc.2012.09.015_bib34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-12-210","article-title":"Has the time come to leave the \u201cwatch-and-wait\u201d strategy in newly diagnosed asymptomatic follicular lymphoma patients?","volume":"12","author":"Rueda","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cmonc.2012.09.015_bib35","first-page":"176","article-title":"Improving our use and understanding of antibodies in B-cell lymphomas","volume":"24","author":"Flowers","year":"2010","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.cmonc.2012.09.015_bib37","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cmonc.2012.09.015_bib38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"15S","key":"10.1016\/j.cmonc.2012.09.015_bib39","article-title":"R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL)","volume":"30","author":"Federico","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.cmonc.2012.09.015_bib40","first-page":"97","article-title":"A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States","volume":"118","author":"Nastoupil","year":"2011","journal-title":"Blood (ASH annual meeting abstracts)"},{"issue":"suppl 4","key":"10.1016\/j.cmonc.2012.09.015_bib41","first-page":"iv89","article-title":"Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study","volume":"22","author":"Morschhauser","year":"2011","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cmonc.2012.09.015_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2012.30.18_suppl.3","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study","volume":"30","author":"Rummel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.cmonc.2012.09.015_bib43","first-page":"405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.cmonc.2012.09.015_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"10.1016\/j.cmonc.2012.09.015_bib45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2010.0129","article-title":"Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice","volume":"8","author":"Rummel","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.cmonc.2012.09.015_bib46","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cmonc.2012.09.015_bib47","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cmonc.2012.09.015_bib48","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9759","key":"10.1016\/j.cmonc.2012.09.015_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cmonc.2012.09.015_bib50","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cmonc.2012.09.015_bib51","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cmonc.2012.09.015_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3816\/CLM.2007.n.034","article-title":"Maintenance therapy in lymphoma","volume":"7","author":"Mihelic","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"10.1016\/j.cmonc.2012.09.015_bib53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.cmonc.2012.09.015_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006552.pub2","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","author":"Vidal","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"32","key":"10.1016\/j.cmonc.2012.09.015_bib55","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cmonc.2012.09.015_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004629.pub2","article-title":"Interferon-alpha for maintenance of follicular lymphoma","author":"Baldo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"10.1016\/j.cmonc.2012.09.015_bib57","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cmonc.2012.09.015_bib58","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"}],"container-title":["Community Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154853151200589X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154853151200589X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T04:57:15Z","timestamp":1594875435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154853151200589X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S154853151200589X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmonc.2012.09.015","relation":{},"ISSN":["1548-5315"],"issn-type":[{"value":"1548-5315","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}